Blueprint Medicines Corp (NASDAQ:BPMC) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $50.51 and last traded at $52.26, with a volume of 14053 shares changing hands. The stock had previously closed at $52.73.
A number of research analysts recently issued reports on BPMC shares. Zacks Investment Research downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, November 2nd. BidaskClub downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Tuesday, November 13th. ValuEngine upgraded Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Wedbush restated an “outperform” rating and set a $101.00 price target on shares of Blueprint Medicines in a report on Monday, October 8th. Finally, Leerink Swann started coverage on Blueprint Medicines in a report on Tuesday, September 25th. They set an “outperform” rating and a $105.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. Blueprint Medicines presently has a consensus rating of “Buy” and a consensus price target of $97.14.
The company has a debt-to-equity ratio of 0.03, a current ratio of 10.05 and a quick ratio of 10.05. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -14.07 and a beta of 1.46.
In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the transaction, the chief executive officer now owns 20,000 shares in the company, valued at approximately $1,269,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Marion Dorsch sold 2,300 shares of the company’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $70.47, for a total value of $162,081.00. Following the transaction, the insider now owns 2,300 shares in the company, valued at approximately $162,081. The disclosure for this sale can be found here. 3.15% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the business. NumerixS Investment Technologies Inc grew its holdings in shares of Blueprint Medicines by 750.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,100 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 4,500 shares during the period. State Board of Administration of Florida Retirement System grew its stake in shares of Blueprint Medicines by 7.4% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 25,236 shares of the biotechnology company’s stock worth $1,602,000 after buying an additional 1,740 shares during the last quarter. grace capital purchased a new stake in shares of Blueprint Medicines in the 2nd quarter worth approximately $171,000. Renaissance Technologies LLC purchased a new stake in shares of Blueprint Medicines in the 2nd quarter worth approximately $15,603,000. Finally, Bollard Group LLC grew its stake in shares of Blueprint Medicines by 38.6% in the 2nd quarter. Bollard Group LLC now owns 53,000 shares of the biotechnology company’s stock worth $3,364,000 after buying an additional 14,750 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: This article was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.wkrb13.com/2018/11/23/blueprint-medicines-bpmc-reaches-new-1-year-low-at-50-51.html.
About Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Story: Ex-Dividend
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.